BioNTech (NASDAQ:BNTX) Shares Gap Up – Here’s What Happened

BioNTech SE Sponsored ADR (NASDAQ:BNTX)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $92.75, but opened at $109.29. BioNTech shares last traded at $115.4230, with a volume of 2,410,449 shares.

BioNTech News Roundup

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: BioNTech announced that it will present new data from its late-stage lung-cancer program at the 2026 World Conference on Lung Cancer. The company plans to highlight its investigational combination of pumitamig and elfetabart drozuntecan, along with progress across its broader oncology pipeline. The upcoming data provide a potential catalyst for the company’s longer-term growth beyond COVID-19 products. BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Combination
• Positive Sentiment: BioNTech initially benefited from investor enthusiasm following Moderna’s cancer-vaccine breakthrough, as traders viewed the results as validation for mRNA-based oncology and potentially supportive of BioNTech’s own cancer pipeline. Unusually heavy call-option buying—8,783 contracts, reportedly 478% above average—also indicated strong speculative interest. Why Is BioNTech Stock Surging on Wednesday?
• Neutral Sentiment: Analyst commentary is focused on BioNTech’s oncology strategy and pipeline, but the available reports do not identify a major new change to earnings estimates or price targets. Investors are therefore likely to focus on future clinical data rather than near-term financial results. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Moderna’s shares reversed sharply after their dramatic prior-session gain, dragging BioNTech and other mRNA-related stocks lower. The move suggests investors are taking profits across the sector rather than assigning immediate value to BioNTech based solely on Moderna’s trial results. Leerink also cautioned that BioNTech’s rally could fade, reinforcing the risk of a short-term pullback. BioNTech’s Rally on Moderna Trial Win Likely to Fade

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Berenberg Bank dropped their target price on BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Sanford C. Bernstein reissued a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. Canaccord Genuity Group set a $142.00 price objective on shares of BioNTech in a research note on Wednesday, August 5th. Morgan Stanley cut their price objective on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. Finally, UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and raised their target price for the stock from $117.00 to $135.00 in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $127.81.

BioNTech Stock Down 2.0%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The firm has a market cap of $28.04 billion, a price-to-earnings ratio of -14.16 and a beta of 1.27. The business’s 50 day moving average price is $92.91 and its 200 day moving average price is $95.64.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business’s revenue for the quarter was down 59.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.60) earnings per share. On average, equities analysts forecast that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

BioNTech declared that its Board of Directors has authorized a share repurchase program on Thursday, May 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to buy up to 4.2% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On BioNTech

Institutional investors have recently modified their holdings of the business. Pictet Asset Management Holding SA grew its stake in BioNTech by 41.6% in the 4th quarter. Pictet Asset Management Holding SA now owns 88,838 shares of the company’s stock valued at $8,457,000 after acquiring an additional 26,119 shares during the period. Monaco Asset Management SAM purchased a new position in BioNTech during the fourth quarter valued at $1,594,000. Hsbc Holdings PLC acquired a new stake in shares of BioNTech in the fourth quarter valued at about $4,969,000. BNP Paribas Financial Markets increased its stake in shares of BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after purchasing an additional 474,796 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after purchasing an additional 166,432 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.